<DOC>
	<DOCNO>NCT00396877</DOCNO>
	<brief_summary>Contemporary management cyanotic congenital heart disease include three stage surgery . Incidence shunt thrombosis death two first stage palliation remain important . The primary objective study evaluate efficacy Clopidogrel 0.2 mg/kg/day reduction cause mortality shunt related morbidity neonates infant cyanotic congenital heart disease palliate systemic-to-pulmonary artery shunt ( e.g . modify Blalock Taussig Shunt [ BTS ] ) . The secondary objective ass safety Clopidogrel study population .</brief_summary>
	<brief_title>Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation</brief_title>
	<detailed_description>In event-driven study , participant randomize treat soon possible shunt placement . They treat follow primary endpoint criterion reach i.e . ( shunt thrombosis , next surgical procedure correction congenital heart disease death ) one year age common study-end-date , ever come first . The common study-en-date defined date project 172 participant would reach primary endpoint criterion .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Cyanotic congenital heart disease treat palliative systemictopulmonary artery shunt . Active bleeding increase risk bleeding , Allergy 2 class drug , Unable receive drug orally enterically , Current clinically significant persistent thrombocytopenia , neutropenia , severe hepatic renal failure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>92 Days</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cyanotic congenital heart disease</keyword>
	<keyword>shunt palliation</keyword>
	<keyword>thrombosis</keyword>
	<keyword>clopidogrel</keyword>
</DOC>